Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Y Pavlov

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 19, 2013
Resampling model of the complement component functional assay: Are we measuring what we think we are measuring?Igor Y Pavlov, Julio C Delgado
Clinical Laboratory|January 14, 2012
Urine TGF- beta1 assay validation: spinning down urine samples could diminish TGF-beta1 signalIgor Y Pavlov, Fuad Shihab, Julio C Delgado
Clinical Laboratory|April 20, 2011
Specificity of EIA immunoassay for complement factor Bb testingIgor Y Pavlov, Nikol De Forest, Julio C Delgado
Transplant Immunology|September 24, 2009
Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective studyJulio C Delgado, Igor Y Pavlov, Fuad S Shihab
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 27, 2012
Reference interval computation: which method (not) to choose?Igor Y Pavlov, Andrew R Wilson, Julio C Delgado
Clinical and Vaccine Immunology : CVI|June 18, 2010
Resampling approach for determination of the method for reference interval calculation in clinical laboratory practiceIgor Y Pavlov, Andrew R Wilson, Julio C Delgado
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 23, 2015
Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximabIgor Y Pavlov, James Carper, Eszter Lázár-Molnár, et al.
The Journal of Investigative Dermatology|November 11, 2011
High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoidesMarshall E Kadin, Igor Y Pavlov, Julio C Delgado, et al.
Clinical & Developmental Immunology|January 11, 2013
Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplantEugene V Ravkov, Igor Y Pavlov, Kimberly E Hanson, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 4, 2025
Expanding the clinical utility of reporter gene assay to infliximab biosimilarsDharmendra Jain, Igor Y Pavlov, Saša Čučnik, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 19, 2013
Resampling model of the complement component functional assay: Are we measuring what we think we are measuring?Igor Y Pavlov, Julio C Delgado
Clinical Laboratory|January 14, 2012
Urine TGF- beta1 assay validation: spinning down urine samples could diminish TGF-beta1 signalIgor Y Pavlov, Fuad Shihab, Julio C Delgado
Clinical Laboratory|April 20, 2011
Specificity of EIA immunoassay for complement factor Bb testingIgor Y Pavlov, Nikol De Forest, Julio C Delgado
Transplant Immunology|September 24, 2009
Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective studyJulio C Delgado, Igor Y Pavlov, Fuad S Shihab
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 27, 2012
Reference interval computation: which method (not) to choose?Igor Y Pavlov, Andrew R Wilson, Julio C Delgado
Clinical and Vaccine Immunology : CVI|June 18, 2010
Resampling approach for determination of the method for reference interval calculation in clinical laboratory practiceIgor Y Pavlov, Andrew R Wilson, Julio C Delgado
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 23, 2015
Clinical laboratory application of a reporter-gene assay for measurement of functional activity and neutralizing antibody response to infliximabIgor Y Pavlov, James Carper, Eszter Lázár-Molnár, et al.
The Journal of Investigative Dermatology|November 11, 2011
High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoidesMarshall E Kadin, Igor Y Pavlov, Julio C Delgado, et al.
Clinical & Developmental Immunology|January 11, 2013
Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplantEugene V Ravkov, Igor Y Pavlov, Kimberly E Hanson, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 4, 2025
Expanding the clinical utility of reporter gene assay to infliximab biosimilarsDharmendra Jain, Igor Y Pavlov, Saša Čučnik, et al.
Pageof 2